Correlation Between Acrivon Therapeutics and Adverum Biotechnologies

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics and Adverum Biotechnologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics and Adverum Biotechnologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics Common and Adverum Biotechnologies, you can compare the effects of market volatilities on Acrivon Therapeutics and Adverum Biotechnologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics with a short position of Adverum Biotechnologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics and Adverum Biotechnologies.

Diversification Opportunities for Acrivon Therapeutics and Adverum Biotechnologies

-0.89

Correlation Coefficient

Acrivon Therapeutics  Adverum Biotechnologies

Pay attention - limited upside

The 3 months correlation between Acrivon and Adverum is -0.89. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics Common and Adverum Biotechnologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adverum Biotechnologies and Acrivon Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics Common are associated (or correlated) with Adverum Biotechnologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adverum Biotechnologies has no effect on the direction of Acrivon Therapeutics i.e., Acrivon Therapeutics and Adverum Biotechnologies go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics and Adverum Biotechnologies

Given the investment horizon of 90 days Acrivon Therapeutics Common is expected to generate 3.38 times more return on investment than Adverum Biotechnologies. However, Acrivon Therapeutics is 3.38 times more volatile than Adverum Biotechnologies. It trades about 0.16 of its potential returns per unit of risk. Adverum Biotechnologies is currently generating about -0.45 per unit of risk. If you would invest  382.00  in Acrivon Therapeutics Common on February 22, 2024 and sell it today you would earn a total of  475.00  from holding Acrivon Therapeutics Common or generate 124.35% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Acrivon Therapeutics Common  vs.  Adverum Biotechnologies

Acrivon Therapeutics

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Acrivon Therapeutics Common are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Acrivon Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Adverum Biotechnologies

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Adverum Biotechnologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in June 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Acrivon Therapeutics and Adverum Biotechnologies

The main advantage of trading using opposite Acrivon Therapeutics and Adverum Biotechnologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics position performs unexpectedly, Adverum Biotechnologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adverum Biotechnologies will offset losses from the drop in Adverum Biotechnologies' long position.

The idea behind Acrivon Therapeutics Common and Adverum Biotechnologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.